ATE259365T1 - Chinolinderivate verwendbar zur hemmung der farnesyl-protein transferase - Google Patents
Chinolinderivate verwendbar zur hemmung der farnesyl-protein transferaseInfo
- Publication number
- ATE259365T1 ATE259365T1 AT00309627T AT00309627T ATE259365T1 AT E259365 T1 ATE259365 T1 AT E259365T1 AT 00309627 T AT00309627 T AT 00309627T AT 00309627 T AT00309627 T AT 00309627T AT E259365 T1 ATE259365 T1 AT E259365T1
- Authority
- AT
- Austria
- Prior art keywords
- protein transferase
- compounds
- quinoline derivatives
- inhibiting farnesyl
- derivatives usable
- Prior art date
Links
- 230000002401 inhibitory effect Effects 0.000 title abstract 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical class N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 title 1
- 102000004357 Transferases Human genes 0.000 title 1
- 108090000992 Transferases Proteins 0.000 title 1
- 229940027991 antiseptic and disinfectant quinoline derivative Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 241000124008 Mammalia Species 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 230000010261 cell growth Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000003528 protein farnesyltransferase inhibitor Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16820799P | 1999-11-30 | 1999-11-30 | |
| US17011999P | 1999-12-10 | 1999-12-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE259365T1 true ATE259365T1 (de) | 2004-02-15 |
Family
ID=26863889
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT00309627T ATE259365T1 (de) | 1999-11-30 | 2000-11-01 | Chinolinderivate verwendbar zur hemmung der farnesyl-protein transferase |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US6596735B1 (de) |
| EP (1) | EP1106612B1 (de) |
| JP (1) | JP2001213876A (de) |
| AT (1) | ATE259365T1 (de) |
| BR (1) | BR0005633A (de) |
| CA (1) | CA2327026A1 (de) |
| DE (1) | DE60008206T2 (de) |
| DK (1) | DK1106612T3 (de) |
| ES (1) | ES2212971T3 (de) |
| MX (1) | MXPA00011856A (de) |
| PT (1) | PT1106612E (de) |
| TR (1) | TR200400342T4 (de) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH11209350A (ja) * | 1998-01-26 | 1999-08-03 | Eisai Co Ltd | 含窒素複素環誘導体およびその医薬 |
| US7053105B2 (en) | 2000-09-25 | 2006-05-30 | Janssen Pharmaceutica, N.V. | Farnesyl transferase inhibiting quinoline and quinazoline derivatives as farnesyl transferase inhibitors |
| US6555581B1 (en) | 2001-02-15 | 2003-04-29 | Jones Pharma, Inc. | Levothyroxine compositions and methods |
| JP2004525109A (ja) | 2001-02-15 | 2004-08-19 | キング・ファーマシューティカルズ・インコーポレイティッド | 安定化された甲状腺ホルモン医薬組成物、及びその製法 |
| US7101569B2 (en) | 2001-08-14 | 2006-09-05 | Franz G Andrew | Methods of administering levothyroxine pharmaceutical compositions |
| AU2003286321A1 (en) | 2002-12-19 | 2004-07-14 | Pfizer Inc. | 2-(1h-indazol-6-ylamino)-benzamide compounds as protein kinases inhibitors useful for the treatment of ophtalmic diseases |
| JP4691041B2 (ja) | 2003-11-20 | 2011-06-01 | チルドレンズ ホスピタル メディカル センター | Ｇｔｐアーゼ阻害剤および使用方法 |
| JP2007516258A (ja) | 2003-12-12 | 2007-06-21 | ワイス | 心臓血管の疾患治療に有用なキノリン誘導体 |
| BRPI0509580A (pt) * | 2004-03-30 | 2007-11-27 | Pfizer Prod Inc | combinações de inibidores de transdução de sinal |
| EP1786777A1 (de) * | 2004-08-26 | 2007-05-23 | Pfizer, Inc. | Aminoheteroarylverbindungen als proteintyrosinkinaseinhibitoren |
| JP4242911B2 (ja) | 2004-08-26 | 2009-03-25 | ファイザー・インク | プロテインキナーゼ阻害薬としてのエナンチオピュアなアミノヘテロアリール化合物 |
| CA2577937C (en) * | 2004-08-26 | 2010-12-21 | Pfizer Inc. | Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors |
| US20060107555A1 (en) * | 2004-11-09 | 2006-05-25 | Curtis Marc D | Universal snow plow adapter |
| WO2007016539A2 (en) | 2005-07-29 | 2007-02-08 | Children's Hospital Medical Center | Gtpase inhibitors and methods of use and crystal structure of rac-1 gtpase |
| SI2447283T1 (sl) | 2005-09-07 | 2015-12-31 | Amgen Fremont Inc. | Človeška monoklonska protitelesa proti aktivin receptorski kinazi-1 (ALK-1) |
| AU2006292278B2 (en) | 2005-09-20 | 2012-03-08 | Osi Pharmaceuticals, Inc. | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
| TW200812615A (en) | 2006-03-22 | 2008-03-16 | Hoffmann La Roche | Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2 |
| AU2007287794B2 (en) | 2006-08-21 | 2013-03-28 | F. Hoffmann-La Roche Ag | Tumor therapy with an anti-VEGF antibody |
| WO2009151910A2 (en) * | 2008-05-25 | 2009-12-17 | Wyeth | Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer |
| US20120189641A1 (en) | 2009-02-25 | 2012-07-26 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
| US20110171124A1 (en) | 2009-02-26 | 2011-07-14 | Osi Pharmaceuticals, Inc. | In situ methods for monitoring the EMT status of tumor cells in vivo |
| US8642834B2 (en) | 2009-02-27 | 2014-02-04 | OSI Pharmaceuticals, LLC | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
| WO2010099138A2 (en) | 2009-02-27 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
| JP2012519282A (ja) | 2009-02-27 | 2012-08-23 | オーエスアイ・ファーマシューティカルズ，エルエルシー | 間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法 |
| WO2011093365A1 (ja) * | 2010-01-27 | 2011-08-04 | 協和発酵キリン株式会社 | 含窒素複素環化合物 |
| AU2011223655A1 (en) | 2010-03-03 | 2012-06-28 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
| AU2011223643A1 (en) | 2010-03-03 | 2012-06-28 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
| WO2012116040A1 (en) | 2011-02-22 | 2012-08-30 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma |
| JP2014519813A (ja) | 2011-04-25 | 2014-08-21 | オーエスアイ・ファーマシューティカルズ，エルエルシー | 癌薬剤発見、診断、および治療におけるｅｍｔ遺伝子シグネチャーの使用 |
| WO2013152252A1 (en) | 2012-04-06 | 2013-10-10 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
| US9980942B2 (en) | 2012-05-02 | 2018-05-29 | Children's Hospital Medical Center | Rejuvenation of precursor cells |
| MY189505A (en) | 2012-10-16 | 2022-02-16 | Janssen Pharmaceutica Nv | Methylene linked quinolinyl modulators of roryt |
| WO2014062655A1 (en) | 2012-10-16 | 2014-04-24 | Janssen Pharmaceutica Nv | HETEROARYL LINKED QUINOLINYL MODULATORS OF RORyt |
| HK1213887A1 (zh) | 2012-10-16 | 2016-07-15 | Janssen Pharmaceutica N.V. | RORγt的苯基连接的喹啉基调节剂 |
| AR094403A1 (es) | 2013-01-11 | 2015-07-29 | Hoffmann La Roche | Terapia de combinación de anticuerpos anti-her3 |
| US9284308B2 (en) | 2013-10-15 | 2016-03-15 | Janssen Pharmaceutica Nv | Methylene linked quinolinyl modulators of RORγt |
| US9403816B2 (en) | 2013-10-15 | 2016-08-02 | Janssen Pharmaceutica Nv | Phenyl linked quinolinyl modulators of RORγt |
| US9221804B2 (en) | 2013-10-15 | 2015-12-29 | Janssen Pharmaceutica Nv | Secondary alcohol quinolinyl modulators of RORγt |
| US9328095B2 (en) | 2013-10-15 | 2016-05-03 | Janssen Pharmaceutica Nv | Heteroaryl linked quinolinyl modulators of RORgammat |
| CA2927182A1 (en) | 2013-10-15 | 2015-04-23 | Janssen Pharmaceutica Nv | Quinolinyl modulators of ror.gamma.t |
| US10555941B2 (en) | 2013-10-15 | 2020-02-11 | Janssen Pharmaceutica Nv | Alkyl linked quinolinyl modulators of RORγt |
| CA2926339A1 (en) | 2013-10-15 | 2015-04-23 | Janssen Pharmaceutica Nv | Alkyl linked quinolinyl modulators of roryt |
| US10028503B2 (en) | 2014-06-18 | 2018-07-24 | Children's Hospital Medical Center | Platelet storage methods and compositions for same |
| WO2017096165A1 (en) | 2015-12-03 | 2017-06-08 | Agios Pharmaceuticals, Inc. | Mat2a inhibitors for treating mtap null cancer |
| CN114450027A (zh) | 2019-08-16 | 2022-05-06 | 儿童医院医疗中心 | 用cdc42特异性抑制剂治疗受试者的方法 |
| WO2021155006A1 (en) | 2020-01-31 | 2021-08-05 | Les Laboratoires Servier Sas | Inhibitors of cyclin-dependent kinases and uses thereof |
| CN120282786A (zh) * | 2022-12-21 | 2025-07-08 | 库拉肿瘤学公司 | 治疗晚期实体肿瘤的方法 |
| WO2024233539A1 (en) * | 2023-05-09 | 2024-11-14 | Kura Oncology, Inc. | Methods of treating squamous cell carcinoma with a farnesyltransferase inhibitor and a pi3k inhibitor |
| WO2025101691A1 (en) * | 2023-11-08 | 2025-05-15 | Exelixis, Inc. | Methods for treating cancer using compounds that inhibit pkmyt1 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW349948B (en) * | 1995-10-31 | 1999-01-11 | Janssen Pharmaceutica Nv | Farnesyl transferase inhibiting 2-quinolone derivatives |
| DE69635966T2 (de) * | 1995-12-08 | 2006-11-30 | Janssen Pharmaceutica N.V. | (Imidazol-5-yl)Methyl-2-Chinolinonderivate als Farnesyl Protein transferase Inhibitoren |
| TW591030B (en) * | 1997-03-10 | 2004-06-11 | Janssen Pharmaceutica Nv | Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N- or C-linked imidazoles |
| IL133212A (en) * | 1997-06-02 | 2005-12-18 | Janssen Pharmaceutica Nv | History of use (imidazolil-5-yl) methyl-2-quinolinone that act as culture inhibitors of smooth muscle cells |
| HRP20000904A2 (en) * | 1998-07-06 | 2001-12-31 | Janssen Pharmaceutica Nv | Farnesyl protein transferase inhibitors for treating arthropathies |
| TR200201296T2 (tr) * | 1999-02-11 | 2002-07-22 | Pfizer Products Inc. | Antikanser maddeleri olarak faydalı heteroaril-ikame edilmiş kinolin-2-on türevleri |
-
2000
- 2000-11-01 ES ES00309627T patent/ES2212971T3/es not_active Expired - Lifetime
- 2000-11-01 DK DK00309627T patent/DK1106612T3/da active
- 2000-11-01 PT PT00309627T patent/PT1106612E/pt unknown
- 2000-11-01 AT AT00309627T patent/ATE259365T1/de not_active IP Right Cessation
- 2000-11-01 DE DE60008206T patent/DE60008206T2/de not_active Expired - Fee Related
- 2000-11-01 EP EP00309627A patent/EP1106612B1/de not_active Expired - Lifetime
- 2000-11-01 TR TR2004/00342T patent/TR200400342T4/xx unknown
- 2000-11-28 US US09/724,464 patent/US6596735B1/en not_active Expired - Fee Related
- 2000-11-28 CA CA002327026A patent/CA2327026A1/en not_active Abandoned
- 2000-11-29 JP JP2000362840A patent/JP2001213876A/ja not_active Withdrawn
- 2000-11-30 BR BR0005633-2A patent/BR0005633A/pt not_active IP Right Cessation
- 2000-11-30 MX MXPA00011856A patent/MXPA00011856A/es active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| CA2327026A1 (en) | 2001-05-30 |
| TR200400342T4 (tr) | 2004-03-22 |
| EP1106612A1 (de) | 2001-06-13 |
| DK1106612T3 (da) | 2004-05-17 |
| PT1106612E (pt) | 2004-06-30 |
| BR0005633A (pt) | 2001-07-17 |
| ES2212971T3 (es) | 2004-08-16 |
| JP2001213876A (ja) | 2001-08-07 |
| US6596735B1 (en) | 2003-07-22 |
| DE60008206D1 (de) | 2004-03-18 |
| EP1106612B1 (de) | 2004-02-11 |
| MXPA00011856A (es) | 2002-06-04 |
| DE60008206T2 (de) | 2004-12-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60008206D1 (de) | Chinolinderivate verwendbar zur Hemmung der Farnesyl-Protein Transferase | |
| ATE242231T1 (de) | Carbonyl-piperaznyl und piperidinyl derivate zur hemmung farnesyl protein transferase | |
| PT1029853E (pt) | Derivados biciclicos heteroaromaticos uteis como agentes anticancerigenos | |
| BG66087B1 (bg) | Хинолинонови производни като тирозин киназни инхибитори | |
| BR9916980A (pt) | Derivados bicìclicos substituìdos úteis como agentes anticancerìgenos | |
| EP1156045A4 (de) | Amid-derivate und drogen-zusammensetzungen | |
| EA200300248A1 (ru) | Бициклопиразолы, активные в качестве ингибиторов киназы, способ их получения и включающие их фармацевтические композиции | |
| HUP0101146A2 (hu) | Foszfolipáz enzim inhibitor hatású indolszármazékok, valamint a vegyületeket tartalmazó gyógyászati készítmények | |
| BR0008202A (pt) | Derivados de quinolin-2-ona substituìdos com heteroarilas úteis como agentes contra o câncer | |
| FI945706A0 (fi) | Proteiinikinaasi C-inhibiittoreita | |
| UY25679A1 (es) | Derivados de quinolin-2-ona inhibidores de la farnesil proteína transferasa útiles como agentes contra el cáncer | |
| TW200613306A (en) | Imidazotriazines as protein kinase inhibitors | |
| ATE321038T1 (de) | Chinolin- und chinazolinderivate und deren verwendung als farnesyl transferase inhibitoren | |
| PT928788E (pt) | Compostos farmaceuticamente activos | |
| TW200420545A (en) | 1-(4-benzyl-piperazin-1-yl)-3-phenyl-propenone derivatives | |
| PT992509E (pt) | Novos derivados macrolidos | |
| WO2001081316A3 (en) | Substituted phenyl farnesyltransferase inhibitors | |
| BG106044A (en) | Substituted 1,4-dihydroindeno[1,2-c]pyrazoles as inhibitors of tyrosine kinase | |
| YU49902A (sh) | Supstituisani derivati piperazina kao mtp inhibitori | |
| NO983444L (no) | Benzo(c)kinolizin derivater, deres fremstilling og anvendelse som 5<alfa>-reduktaseinhibitorer | |
| PT1351954E (pt) | Derivados 4-heterociclil-quinolina e quinazolina inibidores da farnesil-transferase | |
| IL149306A0 (en) | Benzamidine derivatives and pharmaceutical compositions containing the same | |
| EP1565456A4 (de) | 1,2,4-triazolderivat, verfahren zu dessenherstellung, und dieses enthaltende pharmazeutische zusammensetzung | |
| BR9908948A (pt) | Composição farmacêutica contendo um inibidor de protease cisteìna para profilaxia e terapia de dano ao tecido cerebral |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1106612 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |